A first line of defense against the accumulation of misfolded proteins in the endoplasmic reticulum (ER) consists of phosphorylating the a subunit of eukaryotic translation initiation factor 2 (eIF2a) on Ser 51 to decrease protein synthesis, an adaptive stress response essential for survival (1) (2) (3) . Guanabenz (GBZ) can prolong this adaptive response by selectively binding and inhibiting the regulatory subunit of the stress-induced eIF2a phosphatase composed of PPP1R15A and PP1c (4) . GBZ spares the constitutive eIF2a phosphatase PPP1R15B-PP1c, avoiding persistent eIF2a phosphorylation, which would be lethal (5) . As a result, GBZ increases the availability of chaperones to misfolded proteins and consequently rescues cells from proteostasis collapse (4) . Correcting proteostasis defects could, in theory, benefit a broad range of diseases characterized by the accumulation of misfolded proteins (6) . However, identifying a therapeutically valuable approach for progressive diseases represents a double challenge: achieving efficacy without adverse effects. In vivo, GBZ cannot be used to selectively inhibit PPP1R15A because it is a centrally active hypotensive drug with nanomolar affinity for the a2-adrenergic receptor (7) .
Searching for PPP1R15A inhibitors devoid of a2-adrenergic activity, we synthesized GBZ derivatives and identified Sephin1 (selective inhibitor of a holophosphatase) (Fig. 1A) . Like GBZ (4), Sephin1 specifically bound a recombinant fragment of PPP1R15A (amino acids 325 to 636) but not the highly related PPP1R15B (amino acids 340 to 698) (Fig. 1B) . In cells, Sephin1 selectively disrupted the PPP1R15A-PP1c complex but spared the related PPP1R15B-PP1c complex (Fig. 1C) . As a result, Sephin1 prolonged eIF2a phosphorylation after stress (Fig. 1D) , delaying translation recovery (Fig. 1E) . Consequently, Sephin1 attenuated expression of stress genes such as CHOP, a pro-apoptotic protein ( Fig. 1D and  fig. S1 ), because stress gene expression requires translation recovery (8, 9) . Activating transcription factor 4 (ATF4) is selectively translated upon stress when eIF2a is phosphorylated (10) , and this was prolonged in Sephin1-treated cells (Fig. 1D) . In the absence of stress, Sephin1 did not affect eIF2a signaling ( fig. S2 ), which was expected because PPP1R15A is only expressed upon stress (9) . Confirming the selectivity of Sephin1 for PPP1R15A, Sephin1 did not inhibit the catalytic subunit PP1c ( fig. S3 ). Selective inhibition of PPP1R15A by Sephin1 protected cells from cytotoxic ER stress (Fig. 1F  and fig. S4 ), but this was abolished in cells lacking a functional allele of Ppp1r15a (Fig. 1F) . Thus, all the cytoprotective activity of Sephin1 in ERstressed cells resulted from selective inhibition of PPP1R15A. Sephin1 lacked any measurable a2-adrenergic agonist activity in a cell-based assay, in contrast to GBZ (Fig. 1G) . Thus, Sephin1 is a selective PPP1R15A inhibitor.
Pharmacokinetic analysis of Sephin1, administered orally at 1 or 10 mg/kg, revealed that the molecule rapidly disappeared from plasma ( fig.  S5 ) but concentrated in the nervous system, reaching concentrations 7 to 44 times higher in . Data are means T SEM (n = 5 to 7 mice). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. Scale bars, 100 mm. the brain and sciatic nerve (up to~1 mM) than in the plasma ( fig. S5, A and B) , like GBZ does (11) . In humans, the adrenergic agonist activity of GBZ has side effects, including drowsiness and coma, at high doses (12) . In mice, GBZ (1 to 5 mg/kg) also exhibited side effects manifested by a rapid and dose-dependent decrease in rotarod performances ( Fig. 2A) . In contrast, Sephin1-treated mice (1 to 5 mg/kg) continued to run as before treatment (Fig. 2A) . A chronic treatment (1 mg/kg for 1 month) with Sephin1 was also tolerable with no measurable adverse effects on body weight gain in mice (Fig. 2B) . We next evaluated whether Sephin1 had adverse effects on memory because manipulations of PP1c (13) and eIF2a phosphorylation (14) affect memory. In the Morris water maze (15), Sephin1-treated mice showed normal spatial learning and improved their ability to locate a submerged platform as training progressed (Fig. 2, C and D) and remembered where the platform was after it had been removed (Fig. 2E) . In a fear conditioning paradigm, both Sephin1-and vehicletreated mice showed similar basal fear responses during the conditioning phase ( Fig. 2F ) and after (Fig. 2, G and H) . Thus, Sephin1 lacks the adverse effects of GBZ in vivo and has no measurable adverse effect on general health or memory in diverse experimental paradigms. We next examined whether Sephin1 could correct a protein misfolding disease. Deletion of serine 63 of myelin protein zero (MPZ mutant ), a transmembrane protein produced by Schwann cells in the peripheral nervous system, causes the demyelinating neuropathy Charcot-MarieTooth 1B (CMT1B) in humans and a similar disorder in mice. MPZ mutant causes CMT1B by a gain of toxic property associated with pathological signaling through CHOP and PPP1R15A (16, 17) . As previously reported (16, 17) , myelination defects were severe in dorsal root ganglia (DRG) cultures prepared from MPZ mutant mouse embryos (Fig. 3, A and B) . A 2-week treatment with 100 nM of Sephin1 rescued myelination (Fig. 3,  A and B) and decreased the expression of ERstress genes in mutant DRG cultures (Fig. 3C) . Because of the potency of Sephin1 ex vivo (Fig. 3 , A to C) and its pharmacokinetic properties ( fig.  S5 ), we next treated MPZ mutant mice orally twice a day with 1 mg/kg of Sephin1. As reported (18) , MPZ mutant mice exhibited motor defects detectable with rotarod analysis at 4 months of age (Fig. 3D ), but this was completely prevented by Sephin1 (Fig. 3D) . Sephin1 also rescued myelin thickness around axons in sciatic nerves (Fig. 3 , E and F) and reduced the levels of ER-stress markers in MPZ mutant sciatic nerves (Fig. 3 , G and H). Thus, without any obvious adverse effect, Sephin1 prevented the molecular, morphological, and motor defects of the MPZ mutant mice. Selective inhibition of PPP1R15A could in principle ameliorate a broad range of protein misfolding diseases. Mutant and misfolding-prone superoxide dismutase 1 (SOD1) is associated with familial forms of amyotrophic lateral sclerosis (fALS), a motor neuron disease (19) . SOD1 mutants bind to Derlin-1 on the cytosolic side of the ER membrane, blocking degradation of ER proteins and causing ER stress (20) with pathological PPP1R15A signaling (21) . Transgenic mice expressing the human ALS-causing mutant SOD1 G93A (SOD1 mutant mice) develop a motor neuron disease that closely resembles ALS (22) . The motor deficits in SOD1 mutant mice were partially prevented by treatment with 1 mg/kg of Sephin1 twice a day ( fig. S6 ). With 5 mg/kg of Sephin1 once a day, the progressive weight loss of SOD1 mutant mice (Fig. 4A ) as well as their motor deficits (Fig. 4B) were almost completely prevented, without adverse effects on weight gain or motor performance of wild-type mice (Fig. 4, A and B) . The motor deficits of SOD1 mutant mice were associated with motor neuron loss, which was prevented by Sephin1 (Fig. 4, C and  D) . Genetic ablation or pharmacological inhibition of PPP1R15A decreases translation rates and increases the availability of chaperones (4, 23) . To assess whether Sephin1 could improve proteostasis in the cytosol, we monitored aggregation of SOD1 mutant , a defining histopathological feature in ALS (22, 24) . Sephin1 prevented the accumulation of insoluble SOD1 mutant ( Fig.  4E ) and decreased ER stress markers in transgenic spinal cords (Fig. 4F) . Thus, Sephin1 prevented the molecular and organismal defects of SOD1 mutant mice. Here, we have shown that Sephin1 selectively inhibited PPP1R15A to prevent two otherwise unrelated protein misfolding diseases in mice. This was achieved while sparing PPP1R15B, a crucial property because the lack of both PPP1R15A and PPP1R15B is lethal in mice (25) . Thus, PPP1R15A
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Mountain gorillas are an endangered great ape subspecies and a prominent focus for conservation, yet we know little about their genomic diversity and evolutionary past. We sequenced whole genomes from multiple wild individuals and compared the genomes of all four Gorilla subspecies. We found that the two eastern subspecies have experienced a prolonged population decline over the past 100,000 years, resulting in very low genetic diversity and an increased overall burden of deleterious variation. A further recent decline in the mountain gorilla population has led to extensive inbreeding, such that individuals are typically homozygous at 34% of their sequence, leading to the purging of severely deleterious recessive mutations from the population. We discuss the causes of their decline and the consequences for their future survival.
M
ountain gorillas came to the attention of the western world as recently as 1902 (1) and survive today only in two small and critically endangered populations in central Africa (2) . Current estimates place their total population at around 800, of which just over half are in the Virunga volcanic mountain range on the borders of Rwanda, Uganda, and the Democratic Republic of Congo (Fig. 1A) (3, 4) . Mountain gorillas face a number of threats to their continued existence (5), and their survival became an urgent concern during the 1960s, when a precipitous decline in their numbers appeared to put them at grave risk of extinction (6) . Active conservation efforts have since reversed the decline (3), but a loss of genetic diversity associated with small population size may still threaten their long-term viability. Infectious diseases such as Ebola, the cause of substantial recent mortality in the western lowland population (7), represent a particularly serious threat (8) .
Despite extensive study of mountain gorillas in the field, few genetic analyses have been carried out, and these have been confined to mitochondrial sequences and a limited number of autosomal loci (9) (10) (11) . Unlike the other great apes (12) , mountain gorillas have not been studied on a genome-wide scale, which is key to understanding their biology, evolution, and relationship to sister taxa (Fig. 1B) . It is also important in assessing their current status and in forming strategies for future conservation efforts. Phenotypic indicators of inbreeding such as syndactyly have been reported (13, 14) , but the full genetic impact of their decline is unknown. Additionally, the severe population bottleneck experienced by mountain gorillas provides an opportunity to study processes that may have played a recurring role in hominin evolution and extinction.
We performed whole-genome sequencing and analysis for 13 eastern gorillas, comprising seven mountain gorillas from the Virunga volcanoes region and six eastern lowland gorillas. The mountain gorillas originate from both sides of the Virunga massif, including from three groups spanning a densely populated sector on the Rwandan side, and plausibly represent genetic variation and ancestry in the Virunga population at large (15) . Sequencing was performed to an average 26× depth (table S1), and combining these data with published gorilla genome sequences (12) yielded a total data set of 44 samples spanning all four gorilla subspecies (table S2) .
Sequences were aligned to the gorilla reference genome (16) , and several tools were used to call variants across samples (15) . Comparing
